Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UNIPROT:P01178 (
oxytocin
)
15,767
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
We have previously demonstrated that neuronal
oxytocin
mRNA increases during the pubertal development of female rats. In this paper we have examined the factors that regulate this developmental increase in both male and female rats. Northern blot analysis demonstrated that neural
oxytocin
mRNA increased 5- to 10-fold from postnatal day 20 (P20) to P60 in animals of both sexes, coincident with puberty. Mature male rats and females at all stages of the estrous cycle expressed similar levels of neural
oxytocin
mRNA. Pubertal up-regulation of
oxytocin
mRNA was largely, but not completely, inhibited by prepubescent gonadectomy, indicating a requirement for intact gonads as well as some other as yet undefined factor(s). Pubertal treatment of gonadectomized animals with estradiol or testosterone abolished the effects of gonadectomy; treated animals expressed levels of neural
oxytocin
mRNA similar to those in controls. However, treatment of prepubertal animals with estradiol or testosterone from
P10
to P20 had no effect on
oxytocin
mRNA levels, suggesting that neural maturation or other factors are necessary requisites for steroid sensitivity. To determine whether neural activin played any role in regulating
oxytocin
mRNA during puberty, we examined levels of inhibin/activin beta A-chain mRNA. This mRNA was expressed at similar levels in all brain regions and did not vary as a function of gonadectomy or steroid treatment, making it unlikely that activin mediates the observed changes. Together, these data indicate that neural
oxytocin
mRNA is induced by gonadal steroids during puberty, and suggest a mechanism for coordinating development of reproductive functions with other pubertal changes.
...
PMID:Regulation of neural oxytocin gene expression by gonadal steroids in pubertal rats. 208 96
The ontogeny of
oxytocin
receptors in rat forebrain was studied using the selective oxytocin receptor antagonist 125I-d(CH2)5[Tyr(Me)2, Thr4, Tyr-NH29]OVT [( 125I]-OTA). With in vitro receptor autoradiography, binding wa noted on the first postnatal day in dorsal subiculum and thalamus. On postnatal days 5-18, intense labeling was evident in posterior cingulate cortex, dorsal subiculum, lateral septum, and the CA1 subfield of hippocampus. Of these regions only the lateral septum expressed
oxytocin
receptors in adult brain. Competition studies on coronal sections through posterior cingulate, septum, and dorsal subiculum at
P10
demonstrated that transient binding sites in these areas were indeed
oxytocin
selective (OXY greater than AVP greater tha V1 greater than V2). Result of saturation studies on cingulate membranes from 10-day-old pups agreed favorably with previous reports of the kinetics of [125I]-OTA binding to adult
oxytocin
receptors (Kd = 0.1 nM in
P10
cingulate cortex vs. 0.07 nM for adult ventral subiculum). In contrast to these evanescent developmental sites,
oxytocin
receptors in the bed nucleus of the stria terminalis and the ventromedial nucleus of the hypothalamus only appeared in adulthood, presumably in response to the surge of gonadal steroids at puberty.
...
PMID:Ontogeny of oxytocin receptors in rat forebrain: a quantitative study. 255 21
The present study aimed to check the hypothesis concerning the monoamine regulation of the differentiation of their target neurons during ontogenesis. For this aim, neuropeptide gene expression has been evaluated by in situ hybridization in targets for monoamines, differentiating peptidergic neurons, after monoamine depletion in rats during prenatal or early postnatal periods. In the first series of experiments, the vasopressin (VP) and
oxytocin
(OT) mRNA concentrations were measured in the supraoptic nucleus (SON) of rat fetuses at the 21st embryonic day (E21) following daily (E13-E20) treatment with the inhibitor of the catecholamine (CA) synthesis, alpha-methyl-m(p)-tyrosine. Similar study was performed with rats at the 11th postnatal day (P11) after daily (P2-
P10
) treatment with alpha-methyl-m-tyrosine and the neurotoxin, 6-hydroxydopamine. In the second series of experiments, the effect of serotonin (5-HT) depletion by the inhibitor of the 5-HT synthesis, p-chlorophenylalanine, on the vasoactive intestinal polypeptide (VIP) mRNA level in the suprachiasmatic nucleus (SCN) has been studied in fetuses and in neonates as described above. No changes were detected in the VP and OT mRNA concentration in the SON following CA depletion in fetuses, while similar treatment of neonates significantly increased both mRNA levels. On the contrary, the 5-HT depletion caused an increased VIP mRNA concentration in the SCN in fetuses but not in neonates. Thus, our data suggest a monoamine inhibitory influence on peptide gene expression in the differentiating target neurons during certain periods of ontogenesis.
...
PMID:Monoamine influence on neuropeptide gene expression during ontogenesis. 772 32